Scarica l'app Stockscreener
9.50
0.85%
0.08
Dopo l'orario di chiusura:
9.52
0.02
+0.21%
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
2025-01-20 | Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Avanza Fonder AB Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year LowHere's What Happened - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Hennion & Walsh Asset Management Inc. - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Intellia Loses 21.6% in a Week: How Should You Play the Stock? - MSN
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowTime to Sell? - MarketBeat
2025-01-17 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
(NTLA) Technical Pivots with Risk Controls - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation - Markets Insider
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance
Intellia to submit gene-editing therapy NTLA-2002 to FDA in 2026 - Angioedema News Today
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out - Markets Insider
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out - Markets Insider
Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade) - Seeking Alpha
2025-01-14 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out | NDAQ:NTLA | Press Release - Stockhouse Publishing
The Goldman Sachs Group Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $12.00 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect - AccessWire
Intellia Therapeutics - The Pharma Letter
Intellia Therapeutics: Buying The Path To Commercialization (NASDAQ:NTLA) - Seeking Alpha
13 Analysts Have This To Say About Intellia Therapeutics - Benzinga
Intellia Therapeutics (NASDAQ:NTLA) Given New $40.00 Price Target at Oppenheimer - MarketBeat
Intellia stock target cut at Oppenheimer on program discontinuations - Investing.com
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Intellia Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital - Yahoo Finance
Insider Sellers Might Regret Selling Intellia Therapeutics Shares at a Lower Price Than Current Market Value - Simply Wall St
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo - Yahoo Finance
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA) - MarketBeat
Peering Into Intellia Therapeutics's Recent Short Interest - Benzinga
Gene editing stocks drop as Intellia announces layoffs - MSN
Why Is Intellia Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Intellia stock hits 52-week low at $11.34 amid market challenges By Investing.com - Investing.com South Africa
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low After Analyst Downgrade - MarketBeat
Intellia cuts 27% of workforce as it eyes commercial launch - The Business Journals
Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $50.00 at BMO Capital Markets - MarketBeat
Intellia stock hits 52-week low at $11.34 amid market challenges - Investing.com
Wells Fargo & Company Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat
Intellia to stop work on rare disease therapy, lay off staff - BioPharma Dive
CRISPR gene editing company cuts program and jobs - The Pharma Letter
Intellia Therapeutics Restructures to Focus on Late-Stage Programs - TipRanks
Intellia Therapeutics stock falls following strategic reorganization - Investing.com
Intellia Therapeutics stock falls following strategic reorganization By Investing.com - Investing.com Australia
CRISPR biotech Intellia cuts staff as it eyes 2027 launch - pharmaphorum
Intellia to cut 27% of workforce, discontinue NTLA-3001 - MSN
Intellia to cut 27% of workforce, discontinue NTLA-3001 (NTLA:NASDAQ) - Seeking Alpha
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) - The Manila Times
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):